ValiRx plc AI Stock Analysis
Want to see GB:VAL full AI Analyst Report?
ValiRx plc (VAL) AI Stock Analysis
ValiRx plc
(LSE:VAL)
The score is held down primarily by weak financial performance (minimal revenue, negative margins, persistent losses, and continued cash burn that is shrinking equity/assets). Technicals provide partial support with improving short-term momentum (price above key short-term averages and positive MACD), but valuation remains constrained by negative earnings and no dividend support.
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 2.05M
- Dividend Yield
- ―
- Average Volume (3M)
- 15.59M
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.08
- Revenue Growth
- -34.36%
- EPS Growth
- 57.45%
- Country
- UK
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ValiRx plc Business Overview & Revenue Model
Company Description
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat p...
ValiRx plc Financial Statement Overview
Summary
Financials reflect an early-stage, cash-burning biotech: very small and declining revenue, negative gross profit, persistent operating/net losses, and consistently negative operating and free cash flow. Low debt reduces solvency risk, but equity and assets are shrinking as losses accumulate.
Income Statement
18Very NegativeBalance Sheet
42NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.67K | 31.37K | 49.77K | 9,600 | 0 | 0 |
| Gross Profit | -112.46K | -6,250 | -217.22K | -246.04K | -224.27K | -228.79K |
| EBITDA | -1.49M | -2.18M | -1.86M | -2.04M | -2.38M | -1.45M |
| Net Income | -2.14M | -2.23M | -1.92M | -2.04M | -2.41M | -1.55M |
Balance Sheet | ||||||
| Total Assets | 2.77M | 2.63M | 4.26M | 3.13M | 3.98M | 3.52M |
| Cash, Cash Equivalents and Short-Term Investments | 970.56K | 791.61K | 1.56M | 174.68K | 1.14M | 593.67K |
| Total Debt | 0 | 1,395 | 11.86K | 22.07K | 37.71K | 58.72K |
| Total Liabilities | 120.82K | 235.10K | 346.41K | 226.51K | 149.65K | 109.56K |
| Stockholders Equity | 3.13M | 2.86M | 4.32M | 3.22M | 4.05M | 3.60M |
Cash Flow | ||||||
| Free Cash Flow | -1.36M | -1.52M | -1.62M | -2.08M | -1.71M | -1.26M |
| Operating Cash Flow | -1.36M | -1.51M | -1.58M | -1.77M | -1.71M | -1.26M |
| Investing Cash Flow | -2,587 | -13.58K | -38.16K | -306.18K | 0 | 0 |
| Financing Cash Flow | 1.81M | 759.35K | 3.00M | 1.12M | 2.26M | 7,343 |
ValiRx plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Positive. The current price of 0.15 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.14, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 56.22 is Neutral, neither overbought nor oversold. The STOCH value of 54.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VAL.
ValiRx plc Peers Comparison
Overall Rating
GB:VAL49Neutral
GB:SCLP48Neutral
GB:SAR47Neutral
GB:HEMO46Neutral
GB:TCF42Neutral
GB:IMM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | GBP 2.05M | -0.81 | -71.49% | ― | -34.36% | 57.45% | |
| 48Neutral | GBP 98.19M | -4.63 | 128.87% | ― | -100.00% | -30.39% | |
| 47Neutral | GBP 23.75M | -6.04 | -188.01% | ― | ― | 28.78% | |
| 46Neutral | GBP 46.90M | -3.76 | -409.57% | ― | ― | 18.57% | |
| 42Neutral | GBP 4.64M | -1.70 | -93.92% | ― | ― | 55.56% | |
| 37Underperform | GBP 17.59M | -2.25 | -559.87% | ― | ― | 5.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:VAL | ValiRx plc | 0.15 | -0.08 | -34.04% | |
| GB:TCF | Evgen Pharma | 0.17 | -0.04 | -19.05% | |
| GB:IMM | ImmuPharma plc | 2.82 | -7.16 | -71.74% | |
| GB:SAR | Sareum Holdings | 14.50 | 0.75 | 5.45% | |
| GB:SCLP | Scancell Holdings | 81.00 | -19.00 | -19.00% | |
| GB:HEMO | Hemogenyx Pharmaceuticals Plc | 680.00 | -204.00 | -23.08% |
ValiRx plc Corporate Events
ValiRx sees value boost from Ambrose’s AM-Pharma acquisition
PositiveValiRx plc has highlighted the impact of Ambrose Healthcare Ltd’s acquisition of AM-Pharma on its own position, after Ambrose disclosed a deal worth up to €161 million that triggered a share price move in ValiRx. Through its 54.14% owned subsidiary V...
ValiRx tightens operations and bolsters cash as it refocuses pipeline and portfolio
PositiveValiRx has tightened its operations in the first half of 2026, fully implementing a lean strategy that cut administrative costs and delivered additional annual savings, while refocusing Inaphaea BioLabs on supporting the company’s own pipeline throug...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
